180 results on '"Dimopoulou, Maria N."'
Search Results
2. Prognostic Impact of Serum β2-Microglobulin Levels in Hodgkin Lymphoma Treated with ABVD or Equivalent Regimens: A Comprehensive Analysis of 915 Patients
3. Acute Gastrointestinal Graft-versus-Host Disease in Pediatric Patients: Serum Albumin on Day 5 from Initiation of Therapy Correlates with Nonrelapse Mortality and Overall Survival
4. Serum ferritin levels in previously untreated classical Hodgkin lymphoma: correlations and prognostic significance
5. Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma
6. Directed sibling donor cord blood banking for children with β-thalassemia major in Greece: Usage rate and outcome of transplantation for HLA-matched units
7. Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP
8. Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP
9. Rapid clinical-scale propagation of mesenchymal stem cells using cultures initiated with immunoselected bone marrow CD105+ cells
10. Differential Diagnosis of Waldenström's Macroglobulinemia and Other B-Cell Disorders
11. Development and validation of a clinical prediction rule for bone marrow involvement in patients with Hodgkin lymphoma
12. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma
13. Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab
14. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease
15. Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance
16. Hodgkin's lymphoma in first relapse following chemotherapy or combined modality therapy: analysis of outcome and prognostic factors after conventional salvage therapy
17. The splenic form of mantle cell lymphoma
18. Primary Lung Involvement in Waldenströmʼs Macroglobulinaemia: Report of Two Cases and Review of the Literature
19. Differential diagnosis of Waldenstrom's macroglobulinemia from other low-grade B-cell lymphoproliferative disorders
20. Prognostic Implication of the Absolute Lymphocyte to Absolute Monocyte Count Ratio in Patients With Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine or Equivalent Regimens
21. Rapid clinical-scale propagation of mesenchymal stem cells using cultures initiated with immunoselected bone marrow CD105(+) cells
22. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma
23. Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab
24. Rituximab-CHOP (R-CHOP) and radiotherapy (RT) for primary mediastinal large B-cell lymphoma (PMLBCL)
25. Serum free light chain ratio (FLCR) at diagnosis constitute a powerful prognostic factor of survival in multiple myeloma (MM)
26. Treatment of Splenic Marginal Zone Lymphoma With Rituximab Monotherapy: Progress Report and Comparison With Splenectomy
27. Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone with or Without Radiotherapy in Primary Mediastinal Large B-Cell Lymphoma: The Emerging Standard of Care
28. Allogeneic Hematopoietic Stem Cell Transplantation Using An Intravenous Busulfan Based Myeloablative Conditioning without Total Body Irradiation for Pediatric Patients with Acute Lymphoblastic Leukemia
29. The Addition of sFLCR Improves ISS Prognostication in Multiple Myeloma (MM).
30. Efficacy of Rituximab in Hairy Cell Leukemia.
31. Long Term Follow up of Hairy Cell Leukemia (HCL) Patients (PTS) Treated with Interferon-Alpha (IFN-α). The Importance of Maintenance.
32. Rituximab-CHOP (R-CHOP) and Radiotherapy (RT) for Primary Mediastinal Large B-Cell Lymphoma (PMLBCL).
33. Serum Free Light Chain Ratio (FLCR) at Diagnosis Constitute a Powerful Prognostic Factor of Survival in Multiple Myeloma (MM).
34. B-Chronic Lymphoproliferative Disorders (BCLD) Presenting with Splenomegaly: Differential Diagnosis and Outcome.
35. Bortezomib in Patients with Relapsed-Refractory Multiple Myeloma (MM). Clinical Observations.
36. Topoisomerase IIα (TopoIIα) Expression in Hodgkin’s Lymphoma (HL): Correlations with Conventional and Biological Markers and Prognostic Significance under Treatment with ABVD or Equivalent Regimens with or without Radiotherapy (RT).
37. Serum Levels of OPG and MIP-1α in Untreated Multiple Myeloma Patients. Correlations with Staging, Survival and Bone Disease.
38. Excellent Outcome with Rituximab-CHOP (R-CHOP) Combined with Radiotherapy (RT) in Primary Mediastinal Large B-Cell Lymhoma (PMLBCL).
39. Rituximab Monotherapy Is an Effective Treatment for Splenic Marginal Zone B-Cell Lymphomas (SMZL).
40. Retrospective Analysis of 41 Consecutive Patients with Non Gastrointestinal (GI) Extranodal Marginal Zone B-Cell Lymphoma (EMZL): Correlation of Clinical Characteristics and Outcome with Disease Localization.
41. Serum Soluble Syndecan-1 Levels at Diagnosis Constitute an Independent Prognostic Factor of Survival in Myeloma That May Further Differentiate Patients within the ISS Stages.
42. B-Chronic Lymphocytic Leukemia (B-CLL), Small Lymphocytic Lymphoma (SLL) and Waldenstrom’s Macroglobulinemia (MW): A Comparative Fish Analysis.
43. Lymhoma of the Oral Cavity. A Rare Entity with Favorable Prognosis. Ten-Year Experience of a Single Hematology Unit.
44. Interferon Alpha-2B (IFN-a) Is an Effective Agent for the Treatment of Primary Cutaneous T- and B-Cell Lymphoma.
45. Serum Soluble Syndecan-1 Levels Correlate with Erythropoietin and Inversely with Hemoglobin Levels in Untreated Anaemic Myeloma Patients: Possible Role of Syndecan-1 in the Mechanisms of Chronic Anaemia.
46. Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma
47. B‐chronic lymphocytic leukemia: practical aspects
48. Correction of Disease Related Anaemia of B-Chronic Lymphoproliferative Disorders by Recombinant Human Erythropoietin: Maintenance is Necessary to Sustain Response
49. Favorable outcomes of patients with sickle cell disease hospitalized due to COVID-19: A report of three cases.
50. Rapid clinical-scale propagation of mesenchymal stem cells using cultures initiated with immunoselected bone marrow CD105+ cells.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.